Keto on GLP-1: What the Evidence Says About Combining Ketogenic Diets with Semaglutide or Tirzepatide

What do the labels say about diet?

Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight plus at least one weight-related condition [1]. That is a calorie instruction, not a carbohydrate one: the label names no carbohydrate limit [1].

The headline weight figures come from placebo-controlled trials. In STEP 1, 1,961 adults with obesity or overweight and no diabetes lost a mean 14.9% of body weight on semaglutide 2.4 mg weekly versus 2.4% on placebo at 68 weeks, with both arms receiving lifestyle intervention [3]. In SURMOUNT-1, 2,539 adults lost a mean 20.9% at the 15 mg tirzepatide dose versus 3.1% on placebo at 72 weeks [4].

Tirzepatide is a GIP and GLP-1 receptor agonist rather than a pure GLP-1 agonist; Zepbound is the weight-management product and Mounjaro the type 2 diabetes product [2][5].

What is known about ketogenic diets and appetite

A 2015 systematic review and meta-analysis of studies of very-low-energy and ketogenic low-carbohydrate diets found that people on ketogenic low-carbohydrate diets were less hungry and had a reduced desire to eat. The absolute changes in appetite were small and occurred in the context of energy restriction, and the authors concluded that the clinical benefit is in preventing an increase in appetite despite weight loss [6]. That analysis assessed ketogenic diets, not GLP-1 drugs.

Gastrointestinal side effects and dehydration

With Wegovy 2.4 mg in adults with obesity or overweight over up to 68 weeks, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%; 6.8% of treated patients versus 3.2% of placebo patients stopped the drug because of adverse reactions [1]. With Zepbound 15 mg in pooled trials of up to 72 weeks, nausea was 28% versus 8%, diarrhea 23% versus 8%, vomiting 13% versus 2% and constipation 11% versus 5%; 6.7% versus 3.4% discontinued for adverse reactions [2]. Rates from separate trials are not directly comparable [1].

The Wegovy label warns of acute kidney injury due to volume depletion and says to monitor renal function in patients who report reactions that could lead to volume depletion [1]. The label also lists severe gastrointestinal reactions and states that the drug is not recommended in patients with severe gastroparesis [1].

Gallbladder disease and rapid weight loss

In adult weight-management trials, cholelithiasis was reported by 1.6% of Wegovy injection patients versus 0.7% of placebo patients, and cholecystitis by 0.6% versus 0.2% [1]. The label notes that substantial or rapid weight loss can increase the risk of cholelithiasis, and that acute gallbladder disease was still more frequent with Wegovy than with placebo after accounting for the degree of weight loss [1].

If you also take insulin or a sulfonylurea

The Wegovy and Zepbound labels warn that hypoglycemia risk rises when these drugs are combined with insulin or an insulin secretagogue such as a sulfonylurea, including severe hypoglycemia, and suggest considering a lower dose of the insulin or secretagogue when the GLP-1 drug is started [1][2].